Please login to the form below

Not currently logged in
Email:
Password:

kidney disease

This page shows the latest kidney disease news and features for those working in and with pharma, biotech and healthcare.

FDA advisory committee votes against approval of AZ, FibroGen's roxadustat

FDA advisory committee votes against approval of AZ, FibroGen's roxadustat

A US Food and Drug Administration (FDA) advisory committee has voted against approval of AstraZeneca (AZ) and FibroGen’s roxadustat for the treatment of anaemia in chronic kidney disease (CKD) patients. ... New solutions are needed for the six million

Latest news

More from news
Approximately 22 fully matching, plus 146 partially matching documents found.

Latest Intelligence

  • AstraZeneca’s focus on diagnosing and managing chronic kidney disease AstraZeneca’s focus on diagnosing and managing chronic kidney disease

    People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care. ... AstraZeneca's R&D centre in Cambridge, UK. Moderate to severe chronic kidney disease (CKD) is an under-recognised public health

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    4. Vadadustat is an inhibitor of hypoxiainducible factor (HIF)-prolyl hydroxylase (HIF-PH) from Akebia Therapeutics/ Mitsubishi Tanabe Pharma/Otsuka that targets anaemia in chronic kidney disease (CKD). ... Hypercholesterolemia is a major risk of

  • Case study: What we're made of Case study: What we're made of

    If we don’t drink enough water, it can lead to headaches, constipation, tiredness and more serious problems, such as urinary infections and kidney disease. ... This could be a side effect of a condition such as stroke, motor neurone disease, multiple

  • 25 Women Leaders in UK Healthcare 25 Women Leaders in UK Healthcare

    The firm has just signed a long-term collaboration with AZ for the discovery of new drugs for chronic kidney disease and idiopathic pulmonary fibrosis (IPF). ... disease and applying machine learning, artificial intelligence and collapsing analysis to

  • Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019 Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019

    of JAK proteins is an established method of controlling the symptoms of this disease. ... The sales forecast for Zolgensma is $2.09bn. Roxadustat, from AstraZeneca, FibroGen and Astellas, targets anaemia in chronic kidney disease (CKD).

More from intelligence
Approximately 1 fully matching, plus 20 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 6 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...